Arthur J. Gallagher & Co. (NYSE: AJG) — A Top-Decile Compounder That Prints Stock to Buy Growth, On Sale Because It Just Printed a Lot

Independent Equity Research — Fundamental Analysis Report date: 2026-06-14 · Price reference: ~$218.69 (2026-06-12) · Market cap ~$56B · EV ~$68B

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The detailed analysis that follows is deliberately position-free and carries no price target; this opening block is the single place a view is expressed.

Verdict: BUY / accumulate-on-weakness — a top-decile-quality serial compounder at the cheapest valuation it has carried in years, with eyes open to the dilution engine underneath it. Conviction: medium. Directional valuation zone: a base-case fair value of roughly $250–290 (≈21–24x normalized forward adjusted EPS of ~$12, in line with a modest discount to its own 5-year average and to Marsh/Brown & Brown), with attractive accumulation below ~$225 and genuine bull-case optionality to $320–360 if AssuredPartners synergies hit the raised $300M target and organic holds 5–6%. At ~$219 — roughly 18x forward adjusted EPS and a ~34% drawdown from its late-2024 peak — the risk/reward leans favorable for a business that has just compounded adjusted EBITDAC at double digits for 24 consecutive quarters.

The one-line tag: “The roll-up that prints stock to buy growth — marked down because it just printed a lot.” Gallagher is one of five firms that dominate a structurally excellent industry, and on the operating metrics it is arguably the best of them: top-of-class organic growth through the cycle, 36%+ brokerage margins, a claims-TPA crown jewel (Gallagher Bassett) growing double digits, and a 20-year, 750-deal acquisition machine that buys private brokers at ~10–11x EBITDAC and re-rates them into its own ~17x multiple. The de-rating is real and its causes are largely transitory and self-resolving, not structural: to fund the $13.45B AssuredPartners acquisition (the largest broker deal in history, closed August 2025), Gallagher issued ~35M shares — a 16% jump in the share count in a single year — which, combined with a softening P&C pricing cycle that pulled organic growth from 9% toward 5%, and GAAP EPS optically falling (to $5.74) under a wall of acquisition amortization, scared the market into compressing the multiple from ~30x to ~18x. Crucially, adjusted earnings kept compounding while the price fell — that is multiple compression, not deterioration. In factor terms this is an abandoned low-volatility quality name: relative strength is down ~29% over twelve months (a brutal, multi-year-worst stretch), yet the stock is +5.5% over three months — a possible base, not a falling knife.

What keeps conviction at medium rather than high — and what the bears are right to press — is that Gallagher’s per-share compounding is structurally hostage to its own M&A: it is an equity-and-debt-funded roll-up whose reported returns on invested capital are mediocre once the $33B of goodwill and intangibles enter the denominator, whose executive bonus rewards getting bigger (adjusted revenue × EBITDAC growth) rather than returns on capital or TSR, and whose insiders own barely 1.4% of the company. This only works if every deal is bought below Gallagher’s multiple and integrated cleanly. The 20-year record says it usually is — but AssuredPartners is ~4x larger than any prior deal, bought at the rich end (14.3x gross) near a pricing peak, and the cycle is now turning against the assets it bought. What would flip me bullish with conviction: organic holding 5%+ alongside visible AssuredPartners synergy delivery and a credible de-levering path that frees capital for either buybacks or the next accretive deal. What would flip me bearish: organic sagging below 4% for consecutive quarters, an integration stumble or goodwill impairment on AssuredPartners, or a return to large, dilutive, top-of-cycle equity-funded M&A — any of which would say the market’s “deserved-discount” read was right and that post-AssuredPartners Gallagher is a lower-return, higher-leverage version of the compounder it has been.

1. Executive Summary

Arthur J. Gallagher & Co. is the world’s third-largest insurance broker and a leading third-party claims administrator — a capital-light, recurring-fee intermediary that sits between businesses and the global insurance, reinsurance and employee-benefits markets, earning commissions and fees without bearing underwriting risk. It is one of a literal handful of firms (Marsh McLennan, Aon, Willis Towers Watson, Gallagher and Brown & Brown) that dominate a structurally attractive, barrier-protected industry. Gallagher earns ~34% underlying adjusted EBITDAC margins in Brokerage (~36.5% reported in FY2025, flattered by one-time deal-float interest), retains ~95% of clients annually, converts earnings to cash at a high rate (~$1.8B free cash flow in FY2025), and has now delivered 24 straight quarters of double-digit adjusted EBITDAC growth.

The investment tension is not about business quality — by the operating metrics that matter (organic growth, margin expansion, retention), Gallagher is arguably the strongest performer of the Big Five. The tension is about how that growth is financed and what it costs per share. Gallagher runs a two-pronged model — organic growth plus a relentless tuck-in M&A machine (over 750 deals in 20 years) — and it funds the M&A substantially with freshly issued equity and debt. In December 2024 it agreed to buy AssuredPartners, a $2.4–2.9B-revenue middle-market broker, for $13.45B in cash (the largest broker acquisition ever), financing roughly 63% of it by issuing ~35M new shares at $280. The deal closed in August 2025. The result: the share count jumped ~16% in one year, reported (GAAP) EPS fell to $5.74 under a wall of acquisition amortization, net leverage rose to ~2.6x, and — just as a hard P&C pricing market that had powered ~9% organic began to soften toward ~5% — the market de-rated the stock from ~30x adjusted earnings to ~18x, a ~34% drawdown from its late-2024 peak.

Our read: the de-rating overshoots the change in the business. Gallagher’s adjusted EPS rose every year through this period — $8.70 (2023) → $10.10 (2024) → $10.69 (2025) — and is set to step up materially in 2026 as a full year of AssuredPartners and its synergies (target raised from $160M to $300M by early 2028) annualize. Underlying Brokerage margins expanded ~50bps in Q1 2026, organic guidance for 2026 is a healthy ~6%, the claims-TPA business (Gallagher Bassett) re-accelerated to 10% organic, and management is buying tuck-ins at multiples that are falling (10–11.5x) while its own currency is depressed. The bear case — that Gallagher overpaid for a PE roll-up at the cycle top, that its returns on capital are structurally mediocre once goodwill is counted, that its comp rewards empire-building, and that the soft cycle plus integration risk will keep earnings “bumpy” — is coherent and cannot be dismissed. But the weight of evidence favors a high-quality franchise temporarily mispriced for time-limited, self-resolving reasons.

This article takes no position and sets no price target (the single exception is the opinion block above). It frames valuation strictly as embedded expectations and scenarios.

Section verdicts at a glance: Industry — structurally attractive, cyclically softening at the margin. Competitive position — durable, multi-source moat; Gallagher is a share-gaining operator within the oligopoly. Growth — high-quality, decelerating from a cyclical high but still mid-single-digit organic plus a large M&A engine. Financial quality — excellent unit economics and cash conversion, temporarily obscured by acquisition amortization, dilution and one-time items. Capital allocation — a genuine two-sided story: a disciplined, value-creating tuck-in machine, but financed by serial dilution under a size-based incentive, with mediocre reported ROIC. Changes/headwinds — net neutral after the AssuredPartners air-pocket; the cycle is the swing factor. Valuation — cheap versus its own history and reasonable versus peers; the discount is part-deserved, part-mispricing.

2. Business Overview

Arthur J. Gallagher & Co. was founded in 1927 in Chicago, is headquartered in Rolling Meadows, Illinois, and today employs over 72,000 people across roughly 130 countries. It is an intermediary, not a risk-taker: Gallagher does not underwrite insurance or hold insurance risk on its balance sheet. It earns commissions (a percentage of the premium it places) and fees (for advice, administration and claims handling) by connecting clients to the insurance, reinsurance and capital markets, and by advising them on risk and employee benefits. This is the central reason the business is attractive: it captures a slice of an enormous and growing premium pool without bearing the underwriting losses, catastrophe exposure or capital intensity that the insurers it serves must carry.

Two reportable operating segments (plus Corporate):

Brokerage (~87% of revenue) is the core franchise. It spans: (1) retail P/C — placing property, casualty, professional (D&O, cyber), workers’ comp and package coverage for businesses, organized by industry vertical and geography (US, UK, Australia, Canada, New Zealand and beyond); (2) wholesale and specialty — E&S (excess & surplus) lines, binding authorities, programs and Gallagher’s London Specialty operations (marine, aviation, energy, political violence); (3) reinsurance — Gallagher Re, the #3 global treaty/facultative reinsurance broker, created by the December 2021 acquisition of Willis Re; and (4) employee benefits and HR consulting — health, retirement, voluntary benefits, executive benefits and human-capital advisory (substantially expanded by the 2023 Buck acquisition). Gallagher also operates a growing MGA/MGU/programs business (binding underwriting authority on behalf of carriers).

Risk Management (~13% of revenue) is Gallagher Bassett, one of the world’s largest property/casualty third-party claims administrators. When a company self-insures or wants a TPA rather than its carrier’s claims service, Gallagher Bassett settles and administers the claims, provides loss control and risk-management consulting, and runs a proprietary claims platform (RISX-FACS®). Revenue is ~59% workers’ comp, ~34% general/commercial-auto liability, ~7% property. It is a structurally lower-margin business (~21% adjusted EBITDAC margin vs Brokerage’s ~34%) but a steady, sticky, fee-based one — and a genuine differentiator: no other large broker owns a TPA of this scale.

Revenue quality. Revenue is predominantly recurring — commissions and fees on programs that renew annually and are re-bid infrequently — supplemented by fiduciary investment income earned on client cash held in trust ($7.1B of fiduciary cash at YE2025). Client retention runs in the mid-90s%. Management compensation is increasingly fee-based in benefits (advice, plan design, cost management) rather than purely commission-based, which de-links part of the revenue base from premium rate swings. This is a high-quality, capital-light, annuity-like business: capital expenditure is roughly 1% of revenue.

The operating model — “The Gallagher Way.” Gallagher’s defining feature is its culture-led, decentralized-but-integrated roll-up model. Its “two-pronged growth strategy” — grow organically and through mergers — is supported by four strategic pillars: organic growth, M&A, productivity/quality, and culture (codified in the “25 tenets of The Gallagher Way”). The firm runs a continuous tuck-in acquisition machine (typically ~40–50 deals a year), integrating acquired brokers onto common data, systems and cross-sell tools while “preserving” their producer relationships. Proprietary client-facing tools — Gallagher Drive (analytics-led prospecting), the new Blueprint (risk-profile scoring) and AI workbenches in reinsurance and benefits — are positioned as the mechanism that lifts win rates (management cites hit ratios rising from ~32% to ~45% where the tools are deployed) and retention (a full point, from ~94.5% to ~95.5%).

3. Industry Dynamics

The global insurance brokerage industry is one of the best sub-sectors in financials, and understanding why is central to the Gallagher thesis. It is a consolidated oligopoly at the top with a fragmented, capital-saturated roll-up tail beneath it — and Gallagher uniquely straddles both.

Structure — a barrier-protected oligopoly. Large-corporate and global-program broking is led by the “Big Three” — Marsh McLennan (#1), Aon (#2) and Willis Towers Watson (#3) — with Arthur J. Gallagher and Brown & Brown completing the major public set. The large-account tier is effectively closed to new entrants: serving a multinational requires global footprint, deep carrier relationships, specialty depth across dozens of lines, proprietary data, and licensing across scores of jurisdictions. Applying Greenwald’s framework, this is a textbook barrier-protected industry — the dominant firms can be counted on one hand, and share is sticky. The reinsurance-broking channel is even more concentrated: Guy Carpenter (Marsh), Aon Reinsurance Solutions, and Gallagher Re place the large majority of brokered reinsurance globally — a near-triopoly that Gallagher bought its way into via Willis Re in 2021.

The secular demand driver. The cost of risk has been rising faster than GDP — driven by catastrophe frequency/severity, social inflation and litigation, cyber, supply-chain complexity, climate, and the growing share of intangible (uninsured) assets on corporate balance sheets. As risk rises and becomes more complex, the value of expert intermediation rises with it. Gallagher’s proprietary “daily revenue indications” (audits, endorsements, cancellations) are a real-time read on client exposure units — payroll, headcount, revenues, trucks on the road — and management reports these remain in positive territory, meaning client businesses are still growing and buying more coverage. This is the structural tailwind beneath the brokers’ ~5–7% long-run organic growth.

The capital cycle — a genuine Marathon-lens caution, and it is Gallagher’s arena. While the global tier is closed, the middle market is where capital is flooding. Private-equity-sponsored brokers rose from under 10% of brokerage M&A deal volume (2007) to the large majority by the mid-2020s. PE-backed consolidators — Acrisure, Hub International, Howden, BroadStreet, and AssuredPartners itself before Gallagher bought it — bid aggressively for middle-market agencies, and the public majors have paid up to keep pace. Entry multiples for middle-market books have been bid to 10–15x+ EBITDA, eroding forward IRRs on roll-up M&A, and producer-talent competition is intense. This matters directly and centrally for Gallagher, because the middle-market roll-up is its business: AssuredPartners ($13.45B at 14.3x gross EBITDAC) was an acquisition of a PE roll-up, near the capital-attraction peak rather than the trough. That is the classic late-cycle pattern Marathon warns against — high returns attract capital, which compresses future returns. The mitigant: Gallagher buys at a structural discount to its own ~17x public multiple, so even richer entry multiples leave an arbitrage; and management noted on the Q1 2026 call that tuck-in multiples are now falling (to ~10–11.5x) as private sellers re-rate to the public comps and rates soften.

The pricing cycle has rolled over. After the 2019–2024 hard market, commercial P/C rates are now softening. Gallagher’s Q1 2026 data showed property renewal pricing down ~7% (worst in cat-exposed and large risks; some lines approaching 2017 price levels), with casualty up ~4%, professional up ~2%, workers’ comp up ~2%, personal lines up ~4%. Reinsurance saw rate decreases at the 1/1 and 4/1 2026 renewals amid ample capacity. The rate lever is therefore a headwind in 2026–27. Two mitigants distinguish Gallagher from a pure rate-cyclical: (1) much of its revenue is exposure-driven (premiums scale with client payroll/revenue/assets, which are still growing) and fee-based (especially benefits and reinsurance), and (2) management quantifies rate at only ~1–1.5 points of a ~6% organic algorithm, with new business (~2.5 pts) and exposure (~1.5 pts) doing the heavy lifting. The 6% organic Gallagher guides into falling rates supports that claim — but the deceleration from 9% (2023) to a guided ~5.5% Brokerage organic (2026) is real and rate-driven.

Regulation. Brokers are licensed jurisdiction by jurisdiction; the binding constraints are fiduciary handling of client funds and conflict-of-interest/transparency rules (the legacy of the 2004–05 Spitzer-era contingent-commission scandal). A renewed debate over broker-commission and MGA-fee transparency surfaced in 2025 — a watch-item, not yet a thesis risk. On balance, regulation functions more as a barrier to entry than a profit threat. (The 2026 DOJ civil settlement involving “AssuredPartners of South Florida” relates to pre-acquisition conduct at an agency Gallagher never owned and excluded from the deal — a reputational footnote, not a structural or financial issue; see the relevant section.)

Verdict: structurally attractive industry, cyclically softening at the margin, with a capital-cycle caution that lands squarely on Gallagher’s roll-up. The global-tier oligopoly, capital-light no-underwriting-risk model, recurring revenue, and rising-cost-of-risk demand driver make this one of the most durable profit pools in financials over a cycle. Two qualifiers temper it today: the P/C and reinsurance pricing cycle has turned soft (a 2026–27 rate headwind), and capital has flooded the middle-market roll-up that is Gallagher’s core hunting ground — which is precisely where it just deployed $13.45B. Net: a very good industry in which Gallagher competes in both the attractive top tier and the capital-saturated middle, with its competitive execution (below) the reason to believe it can keep winning in both.

4. Competitive Position

The question that decides the thesis is whether Gallagher’s advantage is durable and whether it is eroding. Our answer: the moat is real, multi-source, and not eroding — and on the evidence of organic growth and margin expansion, Gallagher is a share-gaining operator within the oligopoly, not a laggard.

Moat type (Greenwald taxonomy). Gallagher is not protected by proprietary technology in the patent sense — AI and cloud tools are available to all. Its durable advantages are four, in descending order of strength:

1. Demand-side customer captivity / switching costs (the primary moat). Risk and benefits programs are deeply embedded, multi-year, and re-bid infrequently; switching brokers risks coverage gaps and the loss of institutional knowledge about a client’s risk profile. The financial signature is client retention in the mid-90s% (~94.5–95.5%, rising with digital engagement). This passes Greenwald’s “would a number deteriorate without the moat?” test cleanly — strip out captivity and Gallagher would earn sub-scale regional-broker economics rather than 34%+ Brokerage margins.

2. Economies of scale in data, markets and distribution. Scale gives Gallagher: privileged access to insurer capacity (carriers want their products in front of Gallagher’s clients), the ability to spread hundreds of millions of technology spend across a vast revenue base, and proprietary data (the daily revenue indications, claims data from Gallagher Bassett, loss-control analytics). Management’s claim — that connecting reinsurance, commercial-risk and claims data produces insight a sub-scale broker cannot replicate — is credible. But it is a scale advantage shared with the other oligopolists (Marsh’s Blue[i], Aon’s ABS), not unique to Gallagher.

3. The tuck-in acquisition machine itself. This is an under-appreciated, semi-durable advantage. Twenty years and 750+ deals have made Gallagher the acquirer of choice for selling brokers who value culture-fit over the highest PE bid — a reputation and integration playbook (“preserve and enhance,” common systems, cross-sell) that is genuinely hard to replicate and that lets Gallagher buy at ~10–11x and harvest synergies plus multiple-arbitrage. It is a repeatable, learned capability, not a one-off.

4. Gallagher Bassett (the TPA) as a unique asset. No peer of scale owns a claims-administration business this large. It is sticky (claims relationships span years), data-rich (feeding the broking analytics), and counter-cyclical-ish (claims volume is less rate-sensitive). A real point of differentiation.

Where Gallagher is winning. On the metric that matters most — organic growth — Gallagher has led or matched the Big Five through the cycle, and decelerated less than its rate-leveraged peers feared:

(Sources: AJG FY2025 10-K and Q1 2026 call; peer earnings; Aon FY2025 10-K and peer earnings.) Gallagher Bassett’s re-acceleration to 10% organic in Q1 2026 — on new business and retention, not rate — is direct evidence the franchise, not the cycle, drives much of the top line.

Where Gallagher is exposed. Three honest caveats. (1) More cyclical/property-mix exposure than Marsh: Gallagher’s middle-market, E&S and property-heavy book feels the soft property market (down ~7%) more directly, which is why its organic deceleration (9%→~5.5%) is steeper than Marsh’s. (2) The data/analytics moat is shared, not unique — every peer is building the same AI capability. (3) AI disintermediation of commoditized placement is the genuine long-term risk; management argues (plausibly but unprovenly) that AI widens its advantage over sub-scale brokers by amplifying expert advice rather than replacing the broker. This is the single most important thing to monitor.

Verdict: durable, multi-source competitive advantage — switching costs, scale, a proprietary acquisition capability, and a unique TPA — and currently not eroding. Gallagher’s mid-90s retention, 34%+ Brokerage margins, top-of-class organic and 24 straight quarters of double-digit EBITDAC growth are the financial proof. The honest caveats are real (greater property cyclicality, a shared analytics moat, AI as a long-term wildcard) but they qualify rather than undermine the moat. This is a genuinely advantaged operator competing well in a good industry.

5. Growth History and Forward Opportunities

History — a doubling in five years, organic plus M&A. Gallagher’s revenue roughly doubled from $7.0B (2020) to $13.9B (2025), a ~15% revenue CAGR, of which roughly half is organic and half acquired:

(Sources: ROIC; AJG 10-Ks; FY-organic from the 10-K segment notes. 2020–22 organic are directional from older filings/calls.) The pattern is a clear, rate-driven organic deceleration from the hard-market peak (9% in 2023) toward a normalized mid-single-digit (~5.5% guided for 2026), partly offset by Gallagher Bassett’s re-acceleration and a very large M&A contribution (M&A added ~23 points to total revenue growth in Q1 2026, driven by AssuredPartners).

The two-pronged algorithm. Management’s stated long-term model is mid-single-digit organic + tuck-in M&A + margin expansion + the AssuredPartners step-up, compounding to low-double-digit adjusted EPS growth. The components for 2026: (1) organic ~6% (rate ~1–1.5 pts, new business ~2.5 pts, exposure ~1.5 pts); (2) ~40–60bps of underlying Brokerage margin expansion from the productivity/AI pillar; (3) a continuous tuck-in pipeline — 9 deals (~$60M revenue) closed in Q1 2026 with 40+ term sheets (~$400M revenue) in the hopper; and (4) AssuredPartners — a full year of ~$2.4–2.9B revenue plus rising synergies ($160M run-rate by end-2026, raised to up to $300M by early 2028).

Forward opportunities. (1) AssuredPartners synergies and cross-sell — the largest near-term lever; management already sounds more confident on the synergy number two quarters in. (2) Emerging specialty/E&S risks — data centers and AI infrastructure are a structural, multi-year growth vertical that “doesn’t fit the admitted market” and flows to Gallagher’s E&S/specialty desks. (3) Reinsurance (Gallagher Re) — continued share gains in the triopoly; new business overcoming rate headwinds. (4) War/specialty repricing — Middle East-driven marine-war, political-violence and terror coverages are repricing sharply, a net organic tailwind for London Specialty. (5) International expansion and Gallagher Bassett — the TPA is positioned for “fantastic growth” with new products and AI-enabled claims. (6) The roll-up runway remains long — the US middle market is still highly fragmented, and management cites up to $10B of M&A funding capacity over two years without issuing further stock.

Verdict: high-quality but decelerating growth — and increasingly M&A-dependent at the margin. The organic franchise is genuinely good (mid-single-digit, exposure- and new-business-led, with margin expansion on top), but it is decelerating off a cyclical high, and the headline growth rate now leans heavily on AssuredPartners and the tuck-in machine. That is fine if the deals are accretive and integrate — which transfers the growth verdict onto the capital-allocation verdict. Quality of the organic core: high. Sustainability of double-digit total growth: dependent on continued, disciplined M&A.

6. Capital Allocation

This is the section that decides whether Gallagher is a great compounder or a treadmill — and the answer is genuinely two-sided. Capital allocation is the bridge between Gallagher’s excellent business and its shareholder returns, and it runs through one dominant activity: acquisitions, funded by issuing equity and debt.

The model: an equity-and-debt-funded serial roll-up. Management’s revealed priority stack is (1) M&A first, (2) a steady, growing-but-low dividend, (3) opportunistic buybacks only when cash exceeds the deal pipeline, and (4) continuous organic/tech investment. The M&A is funded from operating cash flow, debt, an S-4 stock shelf for stock-funded deals, an at-the-market equity program, and — for transformational deals — large primary equity offerings. Over 20 years and 750+ deals, this has compounded adjusted EPS at a low-double-digit rate and the stock at ~18% annualized over a decade. The engine works because Gallagher buys private brokers at ~10–11x EBITDAC and they re-rate into Gallagher’s ~17x public multiple, with cross-sell and scale synergies on top — a structural multiple arbitrage plus genuine value-add.

The defining 2024–25 event: the AssuredPartners equity raise. To fund the $13.45B AssuredPartners purchase, Gallagher issued 30.4M shares at $280 in December 2024, plus a 4.6M-share green-shoe in January 2025 — ~35M shares, ~$9.6B net, ~63% of the purchase price in fresh equity. Weighted-average diluted shares jumped from 220.5M (2024) to 256.1M (2025) — a ~16% increase in a single year, ~19% over two years. This is the crux of the bear case and the proximate cause of the de-rating: existing holders were diluted ~16%, GAAP EPS fell (to $5.74) as amortization from $16B of new goodwill/intangibles hit the P&L, and the stock — issued at $280 — now trades at ~$219, below the issue price. The deal multiple (14.3x gross EBITDAC, 11.3x net of a $1B deferred tax asset and synergies) is at the rich end of Gallagher’s range, struck near a P/C pricing peak.

The counter-argument (why this can still be value-creating). Three points. (1) It was bought below Gallagher’s own multiple — 14.3x gross vs Gallagher’s ~17x — so even this large, richly-priced deal carries the arbitrage, and management guided ~10–12% adjusted-EPS accretion. (2) It was deliberately equity-heavy to protect the investment-grade rating and avoid leveraging into a softening cycle — a conservative choice, not a reckless one; net leverage at ~2.6x adjusted EBITDAC is manageable and de-levering. (3) The one real governance guard is per-share-aligned: 75% of the CEO’s long-term equity (PSUs) vests on three-year adjusted EBITDAC per share growth — a metric the proxy explicitly says was chosen “to encourage executive officers to be prudent in the use of common stock to finance our M&A activity.” That per-share denominator is the formal check on the dilution treadmill, and management’s track record (the 2023 PSU tranche earned 200% on 14.2% three-year per-share growth) says it has historically cleared the bar.

The genuine governance weaknesses. (1) The annual bonus rewards size, not returns: it is gated by adjusted revenue growth × adjusted EBITDAC growth, with no ROIC, ROE, EPS or relative-TSR metric anywhere — every NEO hit the 200% maximum in FY2025 simply by getting bigger. For a company whose entire value proposition is disciplined capital deployment, the absence of any returns-on-capital or shareholder-return gate is a real flaw. (2) Reported returns on invested capital are mediocre once the $33B of goodwill and intangibles enter the denominator — ROIC.ai computes a single-digit return on total invested capital, and tangible book value per share is negative (-$38.77). ROE looks high (~26–30%) only because the equity base is thin relative to the debt-and-goodwill-funded asset base. (3) Insider ownership is token — the entire officer/director group owns 1.4%, the CEO under 1% — so alignment rests on the incentive design and reputation, not skin in the game.

Dividend and buybacks. The dividend is a steady, multi-decade riser (raised ~8% to $0.70/quarter for 2026, ~$0.72B annualized, ~14 consecutive years of increases) but deliberately low-yield (~1.2%) — a residual after M&A, not a return pillar. Buybacks are negligible by design: zero in 2024 and 2025, with a first-in-years $310M repurchase (1.4M shares) in Q1 2026, framed as opportunistic because management views the equity as “woefully undervalued.” Gallagher is structurally a net issuer, not a repurchaser; the $310M does not meaningfully offset the 35M-share AssuredPartners issuance.

Prior large deals — a record that mostly validates the model. Willis Re (Dec 2021, ~$3.25B + $750M earnout) vaulted Gallagher into the #3 reinsurance-broking tier and is widely judged a success; Buck (2023, $660M) built out benefits/HR consulting; Eastern Insurance (2023, $510M) and My Plan Manager (2023, ~$302M) were larger bolt-ons. AssuredPartners is ~4x the size of any prior deal — a step-change in integration risk, but executed on the same 750-deal playbook that management says is “on plan without exception” two quarters in.

Verdict: a disciplined, value-creating acquisition machine wrapped in a serial-dilution model and a size-based incentive — net favorable, but with eyes open. The 20-year record of accretive M&A and low-double-digit per-share compounding is real and is the heart of the bull case. But the model only works if every deal clears the buy-below-our-multiple-and-integrate bar, and the incentive structure (reward size, ignore returns) plus token insider ownership means the market is trusting the track record and the single PSU per-share guard rather than airtight governance. AssuredPartners is the largest test of that trust in the company’s history. The early signs are good; the verdict is provisional and rides on integration and the cycle.

7. Financial Quality

Unit economics: excellent, and they improve with scale. Gallagher is a capital-light, high-margin, high-cash-conversion business. Brokerage adjusted EBITDAC margins have expanded steadily — 34.2% (2023) → 35.1% (2024) → 36.5% (2025 reported) — and the productivity/AI pillar is delivering ~40–60bps of underlying annual expansion (Q1 2026 underlying expansion was 50bps). Capex is ~1% of revenue. This is a business where incremental revenue drops to the bottom line at high margins and requires almost no incremental capital — the definition of economics that improve with scale.

The critical normalization: one-time deal-float interest. The reported 36.5% FY2025 Brokerage margin is flattered by ~$363M of interest income earned on the AssuredPartners financing proceeds that sat in cash from December 2024 until the August 2025 close. Strip it out and underlying Brokerage margin is closer to ~33.5%. This same float interest distorts year-over-year comparisons throughout 2025 ($143M in Q1, $144M in Q2, $76M in Q3) and reverses in 2026 (Q1 2026 interest/other income fell $161M YoY, knocking ~3.6 points off the optical margin comparison). Any clean read of margin trend must normalize this out — and once normalized, the underlying expansion is genuine but more modest than the headline.

GAAP vs adjusted earnings — the central quality question. GAAP diluted EPS fell to $5.74 in FY2025 (from $6.50), while adjusted EPS rose to $10.69 (from $10.10). The ~$4.95/share gap is almost entirely amortization of acquired intangibles ($2.57/share) plus acquisition integration, restructuring and deal costs. Two things make this gap defensible rather than alarming: (1) the amortization is non-cash, and (2) it is tax-deductible — Gallagher carries ~$11B of tax-deductible amortization plus ~$0.6B of clean-energy tax credits, which together drive cash taxes to roughly 10% of EBITDAC, far below the ~20% book rate. So Gallagher’s cash earnings materially exceed its GAAP earnings, and the adjusted figure is the better proxy for owner earnings. The honest caveat: integration and restructuring add-backs ($257M integration, $183M workforce/lease termination in FY2025) are recurring for a perpetual acquirer — they are a real, ongoing cost of the M&A model, not purely one-time, so a fully conservative “owner earnings” sits somewhat below the headline adjusted figure.

Cash flow and conversion. FY2025 cash from operations was $1.93B (down from $2.58B in 2024), with capex of $145M, for free cash flow of ~$1.785B. The YoY decline in operating cash flow was driven by $491M of earnout payments in excess of original estimates (including a $750M Willis Re earnout paid in April 2025) and working-capital/compensation timing — a one-time drag, not a deterioration in conversion. Underlying cash conversion remains high, consistent with the capital-light model.

Balance sheet. Post-AssuredPartners, Gallagher carries ~$13.1B of total debt against ~$1.4B of cash (~$11.7B net debt) and $23.3B of equity. Net leverage is ~2.6x adjusted EBITDAC (~3.2x on unadjusted EBITDAC) — elevated versus its own history but investment-grade and de-levering, with a long-dated, fixed-rate senior-note maturity profile. The asset side is dominated by $33.3B of goodwill and intangibles (47% of total assets) — the deal-built engine of the GAAP-vs-adjusted gap and the reason tangible book is negative. There is meaningful off-balance-sheet-ish optionality and liability: ~$0.8B of earnout payables (much settleable in cash or stock), and ~$7.1B of fiduciary cash (a pass-through, matched by fiduciary liabilities, but a source of float interest income).

ROIC reality check. The most important quality caveat: on a Greenwald/Marathon lens, Gallagher’s return on the full invested-capital base is mediocre (single digits) because the denominator includes $33B of acquisition goodwill. The business operations earn very high returns on tangible capital (it is capital-light), but the capital deployed to acquire those operations earns a far more ordinary return — which is the mathematical signature of a roll-up that pays up for growth. ROE flatters this (~26–30%) only via leverage and a thin equity base. The bull interpretation: incremental tuck-ins at 10–11x with synergies and re-rating still clear a good return on incremental capital; the bear interpretation: the blended ROIC says shareholders are paying full freight for acquired growth.

Verdict: excellent operating economics that genuinely improve with scale, temporarily obscured by acquisition amortization, dilution, deal-float distortion and one-time cash items — with a real, structural ROIC caveat for the roll-up as a whole. Adjusted/cash earnings are the right lens and they are high-quality and compounding; GAAP optics understate the business. But the returns-on-invested-capital question is the legitimate skeptic’s reply, and it does not fully resolve in the bull’s favor.

8. Changes and Headwinds — Last Two Years

1. AssuredPartners (the dominant change). Signed December 2024, closed August 2025 after clearing a DOJ Second Request with no required divestiture — the largest broker acquisition in history ($13.45B), funded ~63% with equity. It added ~$2.4–2.9B of revenue, ~$16B of goodwill/intangibles, ~16% to the share count, and elevated leverage to ~2.6x. Integration is “on plan without exception” two quarters in, with synergy targets raised from $160M to up to $300M by early 2028. This single event explains most of the stock’s behavior over the period.

2. The pricing cycle turned. The 2019–2024 hard market peaked and rolled over: property pricing is now down ~7%, reinsurance rates are falling, and Gallagher’s Brokerage organic decelerated from 9% (2023) to ~5–6% (2025–26 guide). This is the cyclical headwind, and it lands harder on Gallagher’s property/middle-market-heavy book than on Marsh’s more diversified one.

3. The GAAP-optics air-pocket. GAAP EPS fell to $5.74 in 2025 on dilution and amortization, even as adjusted EPS rose — a presentational headwind that, combined with the equity issuance below the prior price, fed a ~34% drawdown from the late-2024 peak.

4. Dividend raise and first buyback in years. The dividend was raised ~8% to $0.70/quarter, and Gallagher executed a $310M opportunistic buyback in Q1 2026 — small but symbolically notable from a structural net-issuer, signaling management’s “woefully undervalued” view.

5. Prior deals seasoning. Willis Re (2021) paid its $750M earnout in 2025 (a cash-flow drag but a sign the deal hit its revenue targets); Buck and Eastern continue to integrate into benefits/retail.

6. The APSF DOJ settlement (reputational footnote). In 2026 the DOJ reached a civil settlement with “AssuredPartners of South Florida,” an agency Gallagher never owned and excluded from the acquisition, over conduct in 2021–22 (pre-Gallagher). Gallagher states it was identified in diligence, reserved for, and has no impact on the price paid. A quality flag on the acquired franchise’s history, not a financial or structural issue.

7. Leadership continuity. No disruptive leadership change: J. Patrick Gallagher Jr. remains Chairman/CEO, Douglas Howell CFO, with the next-generation Gallaghers (Tom, Patrick) in President/COO roles — continuity that is both a strength (deep institutional knowledge, intact culture) and a mild governance watch-item (family entrenchment with token ownership).

Verdict: net neutral, with the cycle as the swing factor. The period’s defining change — AssuredPartners — is a calculated, mostly-validated bet that has so far tracked to plan; the cyclical softening is a genuine but manageable headwind that Gallagher’s exposure/new-business algorithm largely absorbs. Nothing in the last two years undermines the franchise; the open question is execution on the largest deal in company history into a softening cycle.

9. Risk Analysis (Risk Matrix)

Net risk read: Gallagher’s risks are overwhelmingly execution and capital-allocation risks (integration, dilution, ROIC) plus a manageable cyclical risk (soft pricing) — not existential or balance-sheet risks. The capital-light, no-underwriting-risk model means catastrophic loss is remote. The risks that actually move the thesis are AssuredPartners integration and the durability of organic growth into the soft cycle.

10. Valuation Discussion (Embedded Expectations)

Frame the multiple correctly — use adjusted/cash earnings, not GAAP. Gallagher’s GAAP P/E of ~35–38x is a meaningless artifact of acquisition amortization; the business is correctly valued on adjusted (cash) earnings, EV/EBITDA, and free cash flow. On those measures:

(Sources: ROIC valuation/EV; AJG filings. Forward adjusted EPS is a scenario estimate, not consensus precision.) The key fact: on every cash-based measure, Gallagher trades near the low end of its own multi-year range — roughly 18x forward adjusted EPS versus a stock that spent 2021–2024 at 22–30x, and ~17x EV/EBITDA versus a ~20–24x history. The stock has de-rated, while adjusted earnings have risen.

Versus peers. At ~18x forward adjusted EPS, Gallagher trades roughly in line with Aon (~17.6x forward, based on Aon’s reported figures) and at a discount to Marsh McLennan (which typically commands a premium for its diversification and longer margin-expansion streak), and broadly in line with Brown & Brown. Given Gallagher’s superior organic growth and the AssuredPartners step-up, an in-line-to-Aon multiple is undemanding; a return toward its own historical 22–24x on ~$12 forward adjusted EPS implies a materially higher price.

Embedded-expectations / reverse-DCF read. At ~$219 on ~$12 forward adjusted EPS (~18x), the market is implicitly underwriting: (1) adjusted EPS growth decelerating to roughly high-single-digit (rather than the low-double-digit of the last decade), (2) AssuredPartners delivering its base-case accretion but not upside synergies, (3) continued organic deceleration toward ~5%, and (4) the dilution/ROIC concerns capping any re-rating. In other words, the market is pricing a good-but-no-longer-great compounder. What the bull case argues is mispriced: 24 straight quarters of double-digit EBITDAC growth, a synergy target already being raised, tuck-in multiples falling while the currency is cheap, and a long roll-up runway — a setup more consistent with the historical low-double-digit per-share algorithm than the high-single-digit the multiple implies.

Scenario analysis (illustrative, not a target):

• Bear (~$170–190): organic falls below 4%, AssuredPartners synergies disappoint or a goodwill impairment lands, the soft cycle deepens, and the multiple stays at ~15–16x on ~$11.5 adjusted EPS. The “deserved discount” thesis wins.
• Base (~$250–290): organic holds ~5–6%, AssuredPartners delivers base-case accretion, margins expand ~50bps/year, and the multiple normalizes toward ~21–24x on ~$12 forward adjusted EPS. The compounder re-rates partway back.
• Bull (~$320–360+): organic stays ~6%, AssuredPartners synergies reach the raised $300M, de-levering frees capital for buybacks or the next accretive deal, and the multiple returns to its ~25x+ historical norm on ~$12.5–13 adjusted EPS. The market re-embraces the compounder.

No price target. No recommendation. The above are scenarios bracketing embedded expectations, not a valuation call.

11. Variant Perception

Consensus belief. Sell-side is split-but-cooling: a string of price-target cuts and downgrades-to-Neutral through 2025–26 on “softer organic growth,” AssuredPartners “bumpiness,” and the soft pricing cycle, against a minority bull view (e.g., UBS’s June 2026 upgrade to Buy, PT $250, citing under-appreciated AssuredPartners synergies and AI-driven margin upside). The implicit consensus: a high-quality franchise whose growth is decelerating and whose largest-ever deal adds near-term noise and risk — hold, don’t chase.

The strongest bull case. Gallagher is a top-decile operator (best-in-class organic, 36% Brokerage margins, 24 straight quarters of double-digit EBITDAC growth, a unique TPA) trading at the cheapest multiple in years (~18x forward adjusted EPS, ~17x EV/EBITDA — low end of its own range) because of a temporary, self-resolving confluence: the AssuredPartners equity dilution, GAAP-optics distortion, and a cyclical organic deceleration. Adjusted earnings never stopped compounding. The synergy target is already being raised, tuck-in multiples are falling while the currency is cheap, and the roll-up runway is long. This is a quality-compounder-at-a-reset-price.

The strongest bear case. Gallagher is an equity-funded roll-up that just paid a full price (14.3x gross) for a PE-built middle-market broker at the top of a pricing cycle, diluting holders ~16% in a year, and its reported returns on the $33B goodwill base are mediocre. Its bonus pays for size, not returns; insiders own ~1.4%; tangible book is negative; and organic is decelerating fastest among peers because of its property/middle-market mix. The “deserved discount” view says post-AssuredPartners Gallagher is a lower-return, higher-leverage, more cyclical business than the compounder it was — and 18x is the right multiple, not a bargain.

The 3–5 assumptions that matter most:

1. AssuredPartners accretion and integration — does it deliver ~10–12% accretion and rising synergies, or stumble/impair? (Bull: tracking to plan, synergies raised. Bear: largest deal ever, cycle turning.)
2. Organic durability — does Brokerage organic hold ~5–6%, or break below 4%? (Bull: exposure/new-business-led, fee mix. Bear: rate rolling over, property mix.)
3. Capital-allocation discipline — does management keep buying below its multiple and guard per-share value, or chase size with more dilutive top-of-cycle deals? (Bull: 750-deal record + PSU per-share metric. Bear: size-based bonus, token ownership.)
4. The multiple — does the market re-rate a proven compounder back toward its history, or permanently re-rate the roll-up lower on ROIC concerns? (Bull: cash earnings compounding. Bear: blended ROIC says pay full freight.)
5. AI — does AI amplify Gallagher’s advisory advantage or commoditize placement over time? (The long-term wildcard; currently unprovable either way.)

Factor-positioning read (the tape as evidence). The empirical positioning supports the contrarian-value-in-quality framing, not a momentum or falling-knife read. Gallagher is an abandoned low-volatility quality name: a very low realized market beta (~0.28), a high LowVolatility factor loading (~0.93), and a brutal twelve-month relative-strength collapse (rs_12m −29%, a multi-year worst, with a y1 Sharpe of −1.18). Yet the stock is +5.5% over three months with improving short-horizon momentum (m3 Sharpe +0.46) — a possible base forming after the de-rating, against a stellar long-run track record (10-year return ~18% annualized, Sharpe 0.71). The tape is consistent with a high-quality compounder that the market de-rated and abandoned during the AssuredPartners overhang and cyclical scare, now tentatively stabilizing — evidence that consensus may be offsides to the downside, treating multiple compression as if it were business deterioration.

Where consensus may be wrong: it is extrapolating the GAAP optics (falling EPS) and the organic deceleration as if the franchise were impaired, when the adjusted/cash earnings — the right lens — kept compounding at double digits and the deceleration is cyclical, not structural. The risk to the variant view: consensus is right that the roll-up’s blended returns are mediocre and that AssuredPartners marks a permanent step-down in quality/returns — in which case the de-rating is the market correctly repricing the business, not mispricing it.

12. Fact vs. Interpretation Table

13. Open Questions

1. AssuredPartners standalone trajectory. What is AssuredPartners’ own organic growth into the soft cycle, and is its margin holding? Not separately disclosed; the key unknown behind the integration verdict.
2. De-levering glidepath. Management’s explicit net-debt/EBITDAC target and timeline (discussed on calls, not in the filing) — when does leverage normalize enough to free capital for buybacks or the next large deal?
3. Cash-tax durability. How long does the ~10%-of-EBITDAC cash-tax rate persist as the clean-energy the relevant section credits (~$604M, in runoff) deplete and amortization shields season?
4. Synergy realization. Will the raised $300M synergy target (by early 2028) prove conservative (management hints at upside) or optimistic?
5. Organic floor. Is ~4% core commission/fee organic a genuine floor (as management implied), or does a deeper property/reinsurance softening push it lower?
6. AI. Does AI measurably lift win rates/retention and widen the gap vs sub-scale brokers, or eventually commoditize placement? The longest-dated swing factor.
7. Capital-allocation discipline post-AssuredPartners. Will management resist large, dilutive, top-of-cycle deals and lean into buybacks while the stock is cheap, or return to empire-building?

14. What Must Be True

For the bull case to be right:

• AssuredPartners integrates on plan and delivers ~10–12% accretion with rising synergies (toward $300M) — and no goodwill impairment.
• Brokerage organic holds ~5–6% through the soft cycle, carried by new business and exposure growth as rate fades.
• Management keeps buying tuck-ins below its own multiple and guards per-share value (the PSU metric does its job), with de-levering eventually funding buybacks.
• The market re-rates a proven, compounding franchise back toward its own historical multiple as the GAAP optics clear.
• Falsification test: if, over the next 4–6 quarters, Brokerage organic breaks below 4% and adjusted-EPS growth slips to low-single-digit and AssuredPartners synergies are cut or a goodwill impairment is taken — the “temporary mispricing” thesis is dead; the de-rating was the market correctly repricing a lower-return business.

For the bear case to be right:

• AssuredPartners marks a permanent step-down: a richly-priced, top-of-cycle PE roll-up whose returns disappoint and whose ~$16B of goodwill is at risk.
• The blended ROIC truth reasserts itself: shareholders are paying full freight for serially-acquired growth, financed by dilution under a size-rewarding incentive, with no returns discipline.
• Organic decelerates further as the soft cycle deepens, exposing the property/middle-market mix.
• The multiple stays at ~15–18x (or de-rates further) as the market permanently treats Gallagher as a lower-quality roll-up rather than a premium compounder.
• Falsification test: if adjusted EPS compounds at low-double-digits through 2026–27, organic holds ≥5%, AssuredPartners synergies are raised again, and management executes buybacks while de-levering — the “deserved permanent discount” thesis is falsified, and the stock should re-rate toward its history.

15. Source Appendix

(See the separate Source Appendix file for the full list. Primary sources: AJG FY2021–FY2025 10-Ks, Q1 2026 10-Q, 2026 DEF 14A proxy, AssuredPartners 8-K/8-K-A and offering prospectuses, Q1 2026 earnings-call transcript; ROIC.ai computed fundamentals/valuation; AZI price history and valuation-percentile feed; FactorsToday factor-loading, leaderboard and stock-info endpoints; the AON memo (2026-06-14) for peer/industry framing; public press releases and trade-press for deal terms and analyst actions.)

APPENDIX A — Standard Diligence Questionnaire

Arthur J. Gallagher & Co. (NYSE: AJG) — as of 2026-06-14

Supplemental to the research memo. Answers grounded in the underlying filings and data; Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates: (1) Is the AssuredPartners acquisition (largest broker deal ever, ~63% equity-funded) accretive enough to justify ~16% dilution, or did Gallagher overpay at the cycle top? (2) Is the organic deceleration (9%→~5.5%) cyclical or structural? (3) Why is reported ROIC mediocre, and does the goodwill-heavy roll-up actually create per-share value? (4) Are the large adjusted-EPS add-backs (amortization, integration, restructuring) legitimate “non-cash” items or a recurring cost of the M&A model being dressed up? (5) Will softening P/C pricing compress margins and growth? (6) Is AI a threat or a tailwind to the broking model? UBS’s June 2026 upgrade (Buy, PT $250) crystallized the bull reply: AssuredPartners synergies + AI cost saves are underappreciated.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Off a cyclical high on the rate component — the 2019–2024 hard P/C market is rolling over (property −7%, reinsurance softening), pulling organic from 9% toward ~5–6%. But absolute earnings are still rising (AssuredPartners + tuck-ins + margin expansion), so this is “decelerating off a cyclical pricing peak,” not a cyclical earnings trough. The float-interest line ($363M FY25) is at a cyclical high and normalizing down.

Driven by external environment or internal actions? Both. External: insurance pricing/rate cycle and interest rates (float income). Internal: the controllable two-pronged algorithm — new-business win rates, retention, tuck-in M&A, productivity/AI margin expansion — which management stresses drives the bulk of organic (~4 of ~6 points) independent of rate.

How stable are revenues? Fact: Very stable — recurring commissions/fees on annually-renewing programs, mid-90s% retention, fee-based benefits, and a sticky claims-TPA. Capital-light, no underwriting risk. Revenue has risen every year for over a decade.

Outlook for products/services? How big is the market — growing, shrinking, domestic/international? Fact/Interpretation: The market (global commercial insurance + reinsurance + benefits + claims administration) is large and growing faster than GDP (rising cost of risk, cyber, cat, social inflation, intangible-asset exposure). Gallagher is global (~130 countries) but US-weighted, with growth runways in E&S/specialty (data centers, AI infrastructure), reinsurance, Gallagher Bassett, and the still-fragmented US middle-market roll-up.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? At the top tier, stable oligopoly (5 firms, high barriers). In the middle market, more competitive — PE-backed consolidators have flooded capital in, bidding up agency multiples. Gallagher straddles both.

How profitable is the business (ROIC, ROE)? Fact: High ROE (~26–30%, leverage-aided) and very high returns on tangible operating capital (capital-light). But reported ROIC on the full invested-capital base is mediocre (single-digit) because $33B of acquisition goodwill/intangibles bloats the denominator; tangible book is negative. This is the central quality caveat — see memo the relevant section.

How profitable is the industry — competitors, barriers? Among the best in financials: 30–40% EBITDA margins, recurring revenue, no balance-sheet risk, high barriers to the top tier. Peers: Marsh McLennan, Aon, WTW, Brown & Brown.

Can the business be easily understood? Yes — a fee/commission intermediary plus a claims TPA. The complexity is in the accounting (GAAP-vs-adjusted gap, goodwill, dilution), not the business.

Can it be undermined by foreign low-cost labor? Largely no — it is a local, licensed, relationship- and advice-driven business. Back-office centralization/offshoring is a margin tailwind Gallagher controls.

Do brands matter? Nature of competition? Switching costs? Brand/reputation and trust matter (it is advice and fiduciary handling of client funds). Competition is relationship- and expertise-based (“convince someone to leave a broker they’re happy with”). Switching costs are real (embedded programs, coverage-gap risk, institutional knowledge) — the mid-90s% retention is the proof.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The franchise/intangible value (client relationships, producer talent, the acquisition-integration capability, Gallagher Bassett’s data) far exceeds book; conversely, much intangible value is capitalized as the $33B goodwill/intangibles from acquisitions.

Off-balance-sheet liabilities? Earnout payables (~$0.8B, much settleable in cash or stock — a dilution lever); operating leases; ~$7.1B fiduciary cash matched by fiduciary liabilities (pass-through). No unusual hidden leverage.

How conservative is the accounting? Interpretation: Mixed. The non-GAAP adjusted framework is industry-standard and the amortization add-back is genuinely non-cash and tax-deductible — defensible. But integration/restructuring add-backs ($257M + $183M in FY25) are recurring for a perpetual acquirer, so the headline adjusted EPS slightly flatters true owner earnings. Float-interest flattered FY25 margins ~300bps (disclosed). Net: reasonably transparent, but the reader must normalize.

How CapEx-hungry? Fact: Not at all — capex ~1% of revenue (~$145M FY25). The capital intensity is in acquisitions (M&A), not capex.

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$1.8B FCF FY2025 (CFO $1.93B − capex $145M; CFO depressed by $491M one-time excess earnout payments). Priority stack: M&A first, steady-but-low dividend second, opportunistic buyback third, organic/tech investment continuous.

Significant acquisitions recently? Fact: AssuredPartners ($13.45B, closed Aug 2025) — transformational; plus ~27 tuck-ins in 2025 and Woodruff Sawyer; prior: Willis Re ($3.25B+earnout, 2021), Buck ($660M, 2023), Eastern ($510M, 2023), My Plan Manager (~$302M, 2023).

Buying back shares? Fact: Negligible/by-design — zero in 2024–25; first-in-years $310M (1.4M shares) in Q1 2026. Gallagher is structurally a net issuer.

Issuing large amounts of stock to insiders? No unusual insider issuance; routine option/PSU/ESPP grants. The large issuance is the ~35M-share public offering to fund AssuredPartners.

Compensation policy of directors/management? Fact: CEO total comp $20.7M (FY25). Annual bonus gated by adjusted revenue × EBITDAC growth (size-based; all NEOs hit 200% max). LTI: PSUs (75% of CEO LTI) vest on three-year adjusted EBITDAC per share — the one per-share guard. No ROIC/ROE/EPS/TSR metric — a genuine governance gap. No pledging/hedging; clawback; double-trigger CIC.

Motivations of management? Interpretation: Long-tenured, culture-driven, growth-oriented (founding Gallagher family in C-suite, “The Gallagher Way”). Incentives reward getting bigger; the partial counterweight is the PSU per-share metric and a 20-year track record of accretive deals. Token insider ownership (group 1.4%, CEO <1%) means alignment rests on incentive design and reputation, not a large personal stake.

Valuation & Market Data

ADR, MLP, or K-1 issuer? Fact: No — US-domiciled C-corp, single class of common, issues a standard 1099-DIV. Not an ADR/MLP/K-1.

Dividend policy? Fact: Steady annual raiser (~14 consecutive years; +8% to $0.70/quarter for 2026), deliberately low payout/yield (~1.3%) to preserve M&A firepower.

How profitable is the business? Very (see Business Quality). High margins, high cash conversion, low capex — with the ROIC-on-goodwill caveat.

Is net income diverging from cash from operations? Fact: Yes, structurally and favorably — CFO ($1.93B) exceeds GAAP net income ($1.49B) because of ~$1.1B of non-cash D&A (largely tax-deductible amortization). Adjusted/cash earnings >> GAAP earnings. (FY25 CFO dipped on one-time earnout timing, not a quality break.)

Risks & Downside

What would cause the stock to decline? AssuredPartners integration shortfall or goodwill impairment; organic breaking below ~4%; a deeper P/C pricing crash; another large, dilutive top-of-cycle deal; a permanent ROIC-driven re-rating lower; a broad market/multiple de-rating of quality compounders.

Risk of catastrophic loss? Interpretation: Very low — capital-light, no underwriting risk, diversified across 130 countries and dozens of lines/segments. The realistic downside is valuation/earnings (a lower multiple on slower per-share growth), not impairment of the enterprise.

Chance of total loss? Negligible — investment-grade, cash-generative, diversified, essential intermediary. Total loss is not a realistic scenario.

Recent News & Events

Has the business environment changed recently? Fact: Yes — (1) the P/C pricing cycle softened materially (property −7%, reinsurance falling) through 2025–26; (2) AssuredPartners closed (Aug 2025) and is integrating; (3) interest rates beginning to ease (a future rate cut assumed), reducing float income. The scored news feed is quiet (the main item: UBS upgrade to Buy, June 2026).

Significant acquisitions? AssuredPartners (Aug 2025) — see above.

Change in accounting policies? No material change; ongoing acquisition-accounting (goodwill/intangibles/earnouts) is the dominant accounting feature.

Recent changes — new markets, facilities, management? New growth verticals (data-center/AI-infrastructure E&S, war/specialty repricing); stepped-up AI/productivity deployment (March 2026 Investor Day); leadership continuity (Gallagher family + Howell). No disruptive change.

APPENDIX B — Source Appendix

Arthur J. Gallagher & Co. (NYSE: AJG) — Research as of 2026-06-14

Primary sources first; third-party/computed data and internal framing labeled. Every non-obvious figure in the memo traces to one of the below.

Primary — SEC filings (mirrored locally in output/AJG/sources/)

1. AJG FY2025 Form 10-K (filed 2026-02-17; period 2025-12-31). Segments, adjusted-EPS reconciliation, balance sheet (goodwill $22.6B, intangibles $10.7B, debt ~$13.1B), cash flow, organic growth, clean-energy the relevant section credits, fiduciary cash.
2. AJG Q1 2026 Form 10-Q (filed 2026-05-07; period 2026-03-31). Q1 organic (Brokerage 5%, Risk Mgmt 10%), AssuredPartners-float interest roll-off (~$143M / 41¢), $310M buyback, margin bridge.
3. AJG FY2021–FY2024 Form 10-Ks (filed 2022-02-18, 2023-02-10, 2024-02-09, 2025-02-18). Multi-year organic, margin, share-count and dividend history; Willis Re / Buck / Eastern deal accounting.
4. AJG 2026 DEF 14A proxy (filed 2026-03-23; FY2025 compensation). Executive comp (CEO $20.7M), bonus metrics (adj revenue × EBITDAC growth), PSU per-share-EBITDAC metric, beneficial ownership (insiders 1.4%, CEO <1%, single class).
5. AJG 8-K / 8-K-A — AssuredPartners (closing event 2025-08-18; 8-K-A filed 2025-10-28 with audited AssuredPartners financials and pro formas). Deal close, purchase price, acquired financials.
6. AJG common-stock offering prospectus / FWP (Dec 2024 / Jan 2025). 30.4M shares at $280 + 4.6M green-shoe = ~35M shares / ~$9.6B net for AssuredPartners.
7. AJG Form 4 filings (2025–2026, EDGAR CIK 0000354190). Insider activity — routine grants and tax-withholding; no open-market purchases.

Primary — earnings call

8. AJG Q1 2026 earnings call transcript (2026-04-30). Organic algorithm (rate ~1–1.5 / new business ~2.5 / exposure ~1.5), property −7% RPC, 24 consecutive quarters of double-digit adjusted EBITDAC growth, FY26 organic guide ~6%, AssuredPartners “8 months in / on plan,” synergies raised to $300M by early 2028, tuck-in multiples falling, ~$10B M&A capacity, cash taxes ~10% of EBITDAC, $310M buyback. (Via ROIC.ai transcript tool.)

Third-party — computed fundamentals & market data (reconciled to filings)

9. ROIC.ai — income statement, profitability ratios (ROE, ROIC), enterprise value (market cap ~$56B, EV ~$68B, EV/EBITDA ~17x), valuation multiples (own-history P/E, EV/EBITDA, EV/Sales), per-share data (adjusted/GAAP EPS, negative tangible book −$38.77/sh). Third-party aggregated; EDGAR primary where they differ.
10. AZI price history CSV (azitrading.com download) — daily split/dividend-adjusted OHLCV, EMAs (price ~$218.69 vs 200-EMA ~$238), beta ~0.28.
11. AZI valuation-percentile feed — own-history P/E / P/B / P/S percentiles. Caveat: AZI book value per share ($91.5) is garbled vs ROIC ($23.67); the P/B percentile (9.6) was therefore disregarded; P/E percentile distorted by GAAP amortization — read EV/EBITDA and adjusted P/E instead.
12. AZI scored news feed — quiet tape; principal item: UBS upgrade to Buy, PT $250 (2026-06-09).
13. FactorsToday — factor loadings (LowVolatility ~0.93, low market beta), leaderboard (rs_12m −29%, y1 Sharpe −1.18, m3 +5.5% (+15% ann.), 10-yr return ~18% annualized / Sharpe 0.71), stock-info (relative-strength series). Third-party statistical estimates.

Deal / industry / analyst (public)

14. AssuredPartners acquisition press releases (AJG & GTCR/PRNewswire, 2024-12-09; AJG closing release 2025-08-18). $13.45B, 14.3x gross / 11.3x net EBITDAC, ~$2.4–2.9B revenue, seller GTCR/Apax, ~10–12% accretion, $160M initial synergies.
15. DOJ / antitrust coverage (Second Request 2025-03; cleared without remedy 2025-08-18; separate APSF-South-Florida civil settlement 2026 — excluded agency, pre-AJG conduct). Trade press (Reinsurance News, Business Insurance, StockTitan).
16. UBS analyst note (2026-06-09, via TipRanks/StreetInsider) — upgrade to Buy, PT $250, +70bps above consensus on 2026–28 margins.
17. Prior-deal coverage — Willis Re (Insurance Journal 2021), Buck/Eastern/My Plan Manager (PRNewswire / Insurance Journal / The Insurer, 2023).

Peer / industry cross-read (public)

18. Peer disclosures — Marsh McLennan, Aon, Willis Towers Watson and Brown & Brown 10-Ks and earnings releases (2025) — for the Big-Five oligopoly structure, reinsurance-broking concentration, and peer organic-growth comparison.

Analytical frameworks

19. Competition Demystified (Greenwald & Kahn) and Capital Returns (Marathon Asset Management / Chancellor) — analytical frameworks: the moat-type taxonomy (customer captivity, scale), the capital-cycle lens on middle-market roll-up M&A, and the ROIC/share-stability tests.

Distinguishing Fact / Interpretation / Assumption: see the in-text labels and the Fact-vs-Interpretation table. Third-party computed data (ROIC, AZI, FactorsToday) is reconciled to primary filings; where they conflict, the filing governs.